CN110859940A - Enema for eliminating mass and removing blood stasis and preparation method thereof - Google Patents

Enema for eliminating mass and removing blood stasis and preparation method thereof Download PDF

Info

Publication number
CN110859940A
CN110859940A CN201911242872.8A CN201911242872A CN110859940A CN 110859940 A CN110859940 A CN 110859940A CN 201911242872 A CN201911242872 A CN 201911242872A CN 110859940 A CN110859940 A CN 110859940A
Authority
CN
China
Prior art keywords
parts
enema
eliminating
containing material
stasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911242872.8A
Other languages
Chinese (zh)
Inventor
王刘英
刘凤乐
王蕊蕊
高文全
罗悠悠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dali Bai Autonomous Prefecture Hospital Of Traditional Chinese Medicine
Original Assignee
Dali Bai Autonomous Prefecture Hospital Of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dali Bai Autonomous Prefecture Hospital Of Traditional Chinese Medicine filed Critical Dali Bai Autonomous Prefecture Hospital Of Traditional Chinese Medicine
Priority to CN201911242872.8A priority Critical patent/CN110859940A/en
Publication of CN110859940A publication Critical patent/CN110859940A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/84Valerianaceae (Valerian family), e.g. valerian
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232Angelica
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236Ligusticum (licorice-root)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481Astragalus (milkvetch)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/486Millettia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537Salvia (sage)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/66Papaveraceae (Poppy family), e.g. bloodroot
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/756Phellodendron, e.g. corktree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/78Saururaceae (Lizard's-tail family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994Coix (Job's tears)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a mass-eliminating and stasis-removing enema and a preparation method thereof, wherein the mass-eliminating and stasis-removing enema comprises the following traditional Chinese medicine raw materials in parts by weight: 170g of patrinia 130-containing material, 170g of crude phellodendron bark 130-containing material, 170g of sargentgloryvine stem 130-containing material, 170g of astragalus root 130-containing material, 70-130g of Chinese angelica, 50-70g of salvia miltiorrhiza, 50-70g of ligusticum wallichii, 50-70g of fried rhizoma corydalis, 170g of coix seed 130-containing material, 170g of garden balsam stem 130-containing material, 50-70g of cordate houttuynia, 50-70g of roasted rhizoma zedoariae and 50-70g of crude licorice. The mass-eliminating and stasis-removing enema provided by the invention is simple and easy to prepare, convenient and safe to take and stable in treatment effect.

Description

Enema for eliminating mass and removing blood stasis and preparation method thereof
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a mass-eliminating and stasis-removing enema for treating pelvic inflammation and a preparation method thereof.
Background
Pelvic Inflammation (PID) is inflammation of female internal genitalia and surrounding connective tissues and pelvic peritonitis, belongs to upper genital tract infection, and comprises endometritis, salpingitis, salpingo-oophoroma, pelvic connective tissue inflammation and pelvic peritonitis.
The most important pathogens of pelvic inflammation are Chlamydia Trachomatis (CT) and/or Neisseria Gonorrhoeae (NG), but the proportion of PID is reduced. Symptoms and signs of acute PID vary widely and are often difficult to diagnose. Many PID patients have mild symptoms and are not easily detected. Delayed diagnosis and treatment may lead to sequelae of upper reproductive tract infection such as infertility due to fallopian tube factors and ectopic pregnancy. Laparoscopic diagnosis is more accurate and comprehensive, but endometritis and mild inflammation of the fallopian tubes cannot be found. None of the cases simultaneously diagnosed PID sensitively and specifically based on a single medical history, physical examination or laboratory examination. Some PIDs are asymptomatic or mildly symptomatic and manifest as abnormal bleeding, dyspareunia and vaginal secretions. These asymptomatic or mild PIDs can also lead to infertility. Because PID diagnosis is difficult and has an impact on female fertility, it is desirable to use the lowest diagnostic criteria (including lowest diagnostic criteria, additional diagnostic criteria, most specific criteria).
The western medicine treatment mainly takes antibacterial drug treatment and is performed with operation treatment if necessary. However, long-term application of antibiotics can generate bacterial drug resistance, and researches show that some chronic pelvic inflammatory disease patients have no clinical evidence of bacterial infection, and the disease condition still continues to progress, so that the reason cannot be explained by infectious inflammation alone. Through research on abdominal cavity liquid components of patients with chronic pelvic inflammatory disease, the immune dysfunction is found, and activated immune cells excessively secrete a series of inflammatory mediators, cytokines, growth factors and antibodies, so that further proliferation of pelvic connective tissues is promoted, and the condition is aggravated. The study on microcirculation and hemorheology of patients with chronic pelvic inflammatory disease shows that the patients are often in a state of high viscous blood. Abnormal rheological properties can lead to disorders of blood circulation and microcirculation, leading to a series of serious consequences such as tissue ischemia, hypoxia, metabolism and dysfunction. Therefore, the attack of chronic pelvic inflammatory disease is related to the immune dysfunction of the organism. Therefore, the treatment of chronic pelvic inflammatory disease should regulate immune function, recover the disordered immune function, and simultaneously, be matched with traditional Chinese medicines for promoting blood circulation and removing blood stasis to reduce inflammatory exudation and promote the absorption of inflammatory masses.
The ancient book of traditional Chinese medicine has no pelvic inflammatory disease, but records about the symptoms and etiology and pathogenesis of pelvic inflammatory disease are described in the book of the internal classic. For instance, in the chapter from Huangdi Nei Jing Su, Jiangtong Lun, it is said that "Jue Qi is contained in yin thigh, cold Qi ascends and goes up the abdomen, blood qi is guided downward, so it leads to yin thigh. "Su Wen & bone empty treaty" cloud: "ren Mai is disease … … leukorrhagia and abdominal mass. The pulse is a disease, which is a sudden reversal of qi. "plain questions Yuji Zhenzi Lun of true zang: the spleen is transmitted to the kidney, and the shaoyang disease is manifested as fever, pain and whitish complexion. "and the like. The symptoms are seen in the description of "leukorrhagia", "lower abdominal pain or pain with lower abdomen", "dysmenorrhea", "lumbago", "abdominal mass", "menstrual disorder" and "nonson".
Summarizing doctors' literature in past generations, the disease mainly comprises six excesses attacking, improper diet, seven emotions injuring and internal injury (including sexual overstrain), the disease location is in the cell, uterus and collaterals, the disease nature is mostly deficient and excessive inclusion, qi and blood imbalance and yin and yang, and the related main viscera comprise liver, spleen, kidney, heart, stomach and small intestine.
The Chinese medicine enema is a dosage form which is prepared by preparing Chinese herbal medicines or Chinese patent medicines into liquid and directly filling or dripping into rectum to play a role in systemic or local treatment. Because the focus of pelvic inflammation is mainly in the pelvic cavity, the rectum is adjacent to the uterus and the accessories, the rectal administration makes the liquid medicine directly act on the pelvic cavity, the local concentration is highest, the local blood circulation can be promoted, the blood rheology can be changed, the function of epithelial cilia of lumen mucosa can be enhanced, the tissue adhesion can be dissolved, the conditions of obstruction in the oviduct and the adhesion outside the oviduct can be relieved, and the inflammation can be reduced. Meanwhile, the local medicine directly reaches the focus, which can improve local pain and inflammation symptoms, and remove the adhesion of thickened and thickened accessory tissues and reduce the mass through organized absorption with the functions of promoting blood circulation and removing blood stasis. The veins in the pelvic cavity are rich, and are matched with corresponding organs and vein plexuses formed around the organs, and are communicated with the hemorrhoidal vein plexuses, so that the medicine is absorbed by the hemorrhoidal vein plexuses after entering the rectum, the pelvic cavity can quickly reach effective concentration, and the medicine can be fully absorbed to play pharmacological action after being retained for a long time, thereby obtaining more satisfactory treatment effect. A large amount of literature data also shows that the traditional Chinese medicine enema has obvious advantages for treating the chronic pelvic inflammatory disease.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides the mass-eliminating, blood stasis-removing and intestine-irrigating solution which is simple, convenient and easy to prepare, convenient and safe to take and stable in treatment and is used for treating pelvic inflammation.
The technical purpose of the invention is realized by the following technical scheme:
a mass-eliminating stasis-removing enema comprises the following traditional Chinese medicine raw materials in parts by weight: 170g of patrinia 130-containing material, 170g of crude phellodendron bark 130-containing material, 170g of sargentgloryvine stem 130-containing material, 170g of astragalus root 130-containing material, 70-130g of angelica, 50-70g of salvia miltiorrhiza, 50-70g of ligusticum wallichii, 50-70g of fried rhizoma corydalis, 170g of coix seed 130-containing material, 170g of garden balsam stem 130-containing material, 50-70g of cordate houttuynia, 50-70g of zedoary and 50-70g of crude licorice.
Preferably, the mass-eliminating and stasis-removing enema comprises the following traditional Chinese medicine raw materials in parts by weight: 150g of herba patriniae, 150g of raw phellodendron, 150g of sargentgloryvine stem, 150g of astragalus, 100g of angelica, 60g of salvia miltiorrhiza, 60g of ligusticum wallichii, 60g of fried rhizoma corydalis, 150g of coix seed, 150g of garden balsam stem, 60g of houttuynia cordata, 60g of roasted rhizoma zedoariae and 60g of raw liquorice.
Another objective of the present invention is to provide a method for preparing a mass-eliminating, stasis-removing enema, the method comprising:
respectively weighing 20 parts of herba patriniae, 20 parts of raw phellodendron, 20 parts of sargentgloryvine stem, 20 parts of astragalus, 13.3 parts of angelica, 8 parts of salvia miltiorrhiza, 8 parts of ligusticum wallichii, 8 parts of fried rhizoma corydalis, 20 parts of semen coicis, 20 parts of garden balsam stem, 8 parts of houttuynia cordata, 8 parts of roasted rhizoma zedoariae and 8 parts of raw liquorice;
soaking in 10 times of water for 30min, decocting for 3 times respectively, adding 10 times of water each time for 1 hr, filtering the extractive solution, and mixing filtrates;
separating with tube centrifuge (15000r/min) to obtain clear solution, concentrating to relative density of 1.05-1.15, and packaging;
sterilizing in a rapid cooling sterilizer (sterilization parameter of 121 deg.C, 30min) to obtain enema for removing blood stasis.
Square solution:
herba Patriniae: pungent, bitter and slightly cold. It enters large intestine and liver meridians. Clearing away heat and toxic material, eliminating carbuncle, expelling pus, dispelling blood stasis and relieving pain. Used for treating acute appendicitis, pulmonary abscess, carbuncle, swelling and sore; postpartum abdominal pain due to stasis. Herba Patriniae has inhibitory effect on Staphylococcus aureus, Bacillus dysenteriae, typhoid bacillus, Pseudomonas aeruginosa, and Escherichia coli; it also has effects in resisting hepatitis virus, promoting liver cell regeneration, preventing liver cell degeneration, and improving liver function.
Phellodendron bark: bitter and cold. It enters kidney, bladder and large intestine meridians. Clear heat and dry dampness, purge fire and remove toxicity, remove bone and steam. Can be used for treating leukorrhagia due to damp-heat, stranguria caused by heat, and pain; damp-heat diarrhea and dysentery, jaundice; dampness-heat type beriberi, flaccidity syndrome; bone-steaming, fatigue-heat, night sweat, spermatorrhea; sores, ulcers, swelling, and eczema with pruritus. The product has similar pathogenic microorganism resisting effect to Coptidis rhizoma, and has inhibitory effect on Staphylococcus aureus, hemolytic streptococcus, and various pathogenic bacteria; it also has inhibitory effect on certain dermatophytes, leptospira, hepatitis B surface antigen; the cortex Phellodendri extract has effects of lowering blood pressure, resisting ulcer, tranquilizing, relaxing muscle, lowering blood sugar, and promoting generation of mouse antibody.
Sargentgloryvine stem: bitter and neutral. It enters large intestine and liver meridians. Clearing away heat and toxic material, promoting blood circulation, dispelling pathogenic wind, and relieving pain. Used for treating abdominal pain due to intestinal abscess and pyocutaneous disease due to heat toxin; traumatic injury, amenorrhea, dysmenorrhea; rheumatic arthralgia. The decoction has strong inhibitory effect on Staphylococcus aureus and Streptococcus B, and also has inhibitory effect on Escherichia coli, Staphylococcus albus, Streptococcus catarrhalis, Streptococcus A and Pseudomonas aeruginosa. The water soluble extract can inhibit platelet aggregation, increase coronary blood flow, inhibit thrombosis, increase cAMP level in plasma, improve anoxia resistance of experimental animal, dilate coronary artery, and reduce myocardial infarction.
Astragalus root: sweet and warm. It enters spleen and lung meridians. Invigorating qi, strengthening spleen, invigorating yang, lifting body, consolidating superficial resistance, inducing diuresis, relieving swelling, removing toxic substance, and promoting granulation. Can be used for treating spleen qi deficiency syndrome, lung qi deficiency syndrome, spontaneous perspiration due to qi deficiency, deficiency of both qi and blood, and pyocutaneous disease with difficulty in ulceration and rottenness, or ulcer with difficulty in healing after long-term ulcer. The astragalus membranaceus can promote metabolism of an organism, resist fatigue, promote the renewal of serum and liver proteins, has an obvious diuretic effect, can eliminate experimental nephritis urine proteins, can improve anemic animal phenomena, can raise blood sugar, reduce hyperglycemia, can excite respiration, can enhance and regulate the immune function of the organism, has a promoting effect on an interferon system, and can improve the disease resistance of the organism. Has slight inhibitory effect on cytopathic effect caused by influenza virus and other viruses. Has wide antibacterial effect, and can reduce platelet adhesion, thrombosis, blood lipid, aging and anoxia.
Chinese angelica: sweet, pungent and warm. It enters liver, heart and spleen meridians. Tonify blood, regulate menstruation, activate blood, alleviate pain, moisten intestines to relieve constipation. Can be used for treating blood deficiency; blood deficiency and blood stasis, irregular menstruation, amenorrhea and dysmenorrhea; abdominal pain due to deficiency-cold, traumatic injury, carbuncle, ulcer, and arthralgia due to wind-cold-dampness; constipation due to intestinal dryness due to blood deficiency. The water or alcohol soluble non-volatile substance of radix Angelicae sinensis has exciting effect on isolated uterus, and can strengthen uterine contraction, even produce tonic contraction when administered in large amount or multiple times, and the alcohol soluble substance has stronger effect than water soluble substance.
Red sage root: bitter and slightly cold. It enters heart, pericardium and liver meridians. Promoting blood circulation to regulate menstruation, removing blood stasis to relieve pain, cooling blood to relieve carbuncle, relieving restlessness and tranquilizing mind. Can be used for treating menoxenia, amenorrhea, dysmenorrhea, and puerperal stagnation and pain. Can improve microcirculation and promote blood flow rate; can improve blood rheological property, reduce blood viscosity, etc.
Ligusticum wallichii: pungent and warm. It enters liver, gallbladder and pericardium meridians. Promote blood circulation and move qi, dispel wind and alleviate pain. Can be used for treating pain due to blood stasis and qi stagnation; headache, rheumatic arthralgia. Can reduce the surface activity of blood platelet, inhibit blood platelet aggregation, and prevent thrombosis. The neutral components of the ferulic acid are promoted by a small dose, the uterus smooth muscle is inhibited by a large dose, and the water decoction has a sedative effect on the central nervous system of animals and has an obvious and lasting antihypertensive effect.
Rhizoma corydalis: pungent, bitter and warm. It enters heart, liver and spleen meridians. Activate blood, move qi and alleviate pain. It is indicated for pain due to qi and blood stagnation. Tetrahydropalmatine has analgesic, hypnotic, tranquilizing, and tranquilizing effects. The alcohol extract can dilate coronary artery, reduce coronary artery resistance, increase coronary artery blood flow, and improve anoxia resistance.
Coix seed: sweet, bland and cool. It enters spleen, stomach and lung meridians. Induce diuresis and drain dampness, invigorate spleen, remove arthralgia, clear heat and expel pus. Used for edema, dysuria and beriberi; diarrhea due to spleen deficiency; spasm of damp arthralgia; pulmonary abscess and intestinal abscess.
Garden balsam stem: pungent and warm. It enters lung, liver, kidney and stomach meridians. Expelling wind and removing dampness, promoting blood circulation and removing obstruction in collaterals, dispelling cold and relieving pain, eliminating phlegm and relieving asthma. Can be used for treating rheumatalgia, numbness of limbs, traumatic injury, swelling and pain due to blood stasis, cold pain in gastric cavity, wind-cold type common cold, cough, asthma, dysmenorrhea, and amenorrhea. The product has anti-inflammatory effect by inhibiting capillary permeability, and has obvious analgesic effect on thermal pain; the garden balsam stem volatile oil has broad-spectrum antibacterial activity, and the garden balsam stem volatile oil has inhibitory effect on staphylococcus aureus, pseudomonas aeruginosa, escherichia coli and proteus.
Houttuynia cordata: pungent and slightly cold. It enters lung meridian. Clearing away heat and toxic material, curing abscess and discharging pus, inducing diuresis and treating stranguria. Can be used for treating pulmonary abscess, suppuration, and cough due to lung heat; sores and abscess due to heat-toxicity; syndrome of stranguria due to damp-heat. The houttuynin has different degrees of inhibition effects on various gram positive bacteria and negative bacteria such as staphylococcus aureus, diplococcus pneumoniae and the like; also has antiviral effect. The product has effects in improving phagocytic ability of leukocyte, enhancing immunity, and relieving inflammation.
Zedoary turmeric: pungent, bitter and warm. It enters liver and spleen meridians. Break blood and move qi, resolve food stagnation and alleviate pain. Can be used for treating abdominal mass, amenorrhea, pain in heart and abdomen, and abdominal distention and pain due to dyspepsia. The volatile oil preparation has direct destruction effect on various cancer cells, and can enhance specific immunity through immune system to obtain detailed immune protection effect. Can inhibit the growth of various pathogenic bacteria, and has effects of inhibiting local edema and inflammation of mice. Zedoary turmeric oil has obvious effect of resisting gastric ulcer. The water extract can inhibit platelet aggregation, promote the restoration of arteriolar blood flow, completely prevent arteriolar contraction, and promote the restoration of local microcirculation. The zedoary turmeric aqueous ethanol extract has effect in inhibiting thrombosis in vivo.
The licorice root is sweet and neutral. It enters heart, lung, spleen and stomach meridians. Invigorating spleen and replenishing qi, eliminating phlegm and relieving cough, relieving spasm and pain, clearing heat and detoxicating, and harmonizing the other drugs. Can be used for treating heart-qi deficiency, intermittent pulse, and palpitation; spleen qi deficiency; cough and asthma; spasm and pain of abdomen and limbs; sores and ulcers due to heat-toxin, swollen and sore throat, and poisoning due to medicine and food; harmonizing the drug property. Glycyrrhrizae radix has effect of resisting arrhythmia; has antiulcer, gastric acid secretion inhibiting, smooth muscle spasm relieving, and analgesic effects, and has synergistic effect with paeoniflorin; has antibacterial, antiviral, antiinflammatory, and antiallergic effects; it also has diuretic, blood lipid reducing, and liver protecting effects.
The traditional Chinese medicine composition has the effects of promoting blood circulation to remove blood stasis, clearing heat and promoting diuresis, regulating qi to alleviate pain, promoting absorption of inflammation, smoothing blood vessels, removing adhesion and hyperplasia of pelvic tissues, and achieving the effects of resisting inflammation, reducing swelling and relieving pain.
Case or clinical data
According to the invention, 90 cases of pelvic inflammation patients are clinically observed, the patients are 20-50 years old and the disease course is 6 months-4 years, 84 cases of pelvic inflammation-eliminating and stasis-removing enema liquid provided by the invention are cured after being taken for 3 courses of treatment, the cure rate is 93.3%, 87 cases of pelvic inflammation-eliminating and stasis-removing enema liquid are effective, and the effective rate is 96.7%.
The invention has the beneficial effects that:
the mass-eliminating and stasis-removing enema provided by the invention is simple and easy to prepare, and convenient and safe to take. The traditional Chinese medicine enema is administrated through intestinal tract, the preparation quality requirement is relatively low, the production process is simple and convenient, the traditional Chinese medicine enema is easy to prepare solution type, colloid type, emulsion type and suspension type liquid medicines, the treatment is relatively stable, the medicines are selectively absorbed on the intestinal mucosa, and the mass-eliminating, blood stasis-removing and intestine-irrigating liquid can promote blood circulation to remove blood stasis, clear heat and promote diuresis, regulate qi to alleviate pain, promote the absorption of inflammation, smoothen blood vessels, and relieve the adhesion and hyperplasia of pelvic tissues, and has the effects of resisting inflammation, reducing swelling and relieving pain.
Detailed Description
The present invention is further illustrated by the following examples.
Example 1
A mass-eliminating stasis-removing enema comprises the following traditional Chinese medicine raw materials in parts by weight: 140g of herba patriniae, 160g of raw phellodendron, 130g of sargentgloryvine stem, 130g of astragalus, 80g of angelica, 50g of salvia miltiorrhiza, 50g of ligusticum wallichii, 50g of fried rhizoma corydalis, 140g of coix seed, 160g of garden balsam stem, 50g of houttuynia cordata, 50g of roasted rhizoma zedoariae and 50g of raw liquorice.
Example 2
A mass-eliminating stasis-removing enema comprises the following traditional Chinese medicine raw materials in parts by weight: 160g of herba patriniae, 140g of raw phellodendron, 170g of sargentgloryvine stem, 170g of astragalus, 110g of angelica, 70g of salvia miltiorrhiza, 70g of ligusticum wallichii, 70g of fried rhizoma corydalis, 160g of coix seed, 130g of garden balsam stem, 70g of houttuynia cordata, 70g of roasted rhizoma zedoariae and 70g of raw liquorice.
Example 3
A mass-eliminating stasis-removing enema comprises the following traditional Chinese medicine raw materials in parts by weight: 150g of herba patriniae, 150g of raw phellodendron, 150g of sargentgloryvine stem, 150g of astragalus, 100g of angelica, 60g of salvia miltiorrhiza, 60g of ligusticum wallichii, 60g of fried rhizoma corydalis, 150g of coix seed, 150g of garden balsam stem, 60g of houttuynia cordata, 60g of roasted rhizoma zedoariae and 60g of raw liquorice.
Example 4
Preparation method of enema for eliminating mass and removing blood stasis
Respectively weighing 20 parts of herba patriniae, 20 parts of raw phellodendron, 20 parts of sargentgloryvine stem, 20 parts of astragalus, 13.3 parts of angelica, 8 parts of salvia miltiorrhiza, 8 parts of ligusticum wallichii, 8 parts of fried rhizoma corydalis, 20 parts of semen coicis, 20 parts of garden balsam stem, 8 parts of houttuynia cordata, 8 parts of roasted rhizoma zedoariae and 8 parts of raw liquorice; (Components of examples 1, 2 and 3 above were used)
Soaking in 10 times of water for 30min, decocting for 3 times respectively, adding 10 times of water each time for 1 hr, filtering the extractive solution, and mixing filtrates;
separating with tube centrifuge (15000r/min) to obtain clear solution, concentrating to relative density of 1.05-1.15, and packaging;
sterilizing in a rapid cooling sterilizer (sterilization parameter of 121 deg.C, 30min) to obtain enema for removing blood stasis.
Example 5
The invention discloses an extraction process optimization test of mass-eliminating stasis-removing enema liquid
The test method comprises the following steps:
1. design of orthogonal experiments
Selecting 3 conditions of water addition amount (A), extraction time (B) and extraction frequency (C) as investigation factors according to the conditions of the decocting method, wherein each factor takes 3 levels according to the actual situation, and taking berberine hydrochloride content and dry extract yield of the extract as evaluation indexes, and L9 (3)4) The test was arranged and the factor levels are shown in table 1.
TABLE 1 factor level table
Tab 1 Factors and levels of orthogonal test
Figure BDA0002306747340000101
2. Determination of extract yield
Precisely sucking 1mL of 9 orthogonal sample solutions under the item of 2.1.3, respectively, placing in a halogen moisture tester, measuring water content according to set measurement conditions (temperature program: step; drying temperature: 0-4min, raising to 200 deg.C, lowering to 105 deg.C after 4min, closing mode: 60min, measuring time: 5min), and calculating extract yield.
Results and analysis according to orthogonal experimental design, berberine hydrochloride content and extract yield are calculated, multi-index comprehensive weighting scoring is carried out, and the results are shown in table 2. To further determine the effect of each factor on the results, analysis of variance was performed on the test results, and the results are shown in table 3.
TABLE 2 orthogonal test arrangement and results
Tab 2 Results of orthogonal experiment
Figure BDA0002306747340000102
Figure BDA0002306747340000111
Note: comprehensive scoring formula
Figure BDA0002306747340000112
X max is the maximum value of the extract yield and is counted as 0.3, and Y max is the maximum value of the berberine hydrochloride content and is counted as 0.7.
TABLE 3 ANOVA TABLE
Tab 3 Variance analysis
Figure BDA0002306747340000113
Note: f0.05(2,2) 19.00, F0.01(2,2) 99.00, significance
From the extreme value and the ANOVA table, it can be found that the factors influencing the extraction process of the gynecological enema liquid are C (the extraction times)>A (Water adding quantity)>B (decoction time), and the number of extractions is a significant influence factor (P)<0.05), factor A, B had no significant effect on the test results. Thus, the optimum level combination of the factors is determined to be A2B2C3The decoction is carried out for 3 times, 10 times of water is added each time, and each time lasts for 1 hour.
3. Process verification test is called respectivelyTaking 3 parts of prescription medicinal materials in 5 times, and performing the preferred extraction process A2B2C3The results of the verification test are shown in Table 4, and the RSD is 1.6%, which indicates that the optimized process conditions are stable, reasonable and feasible.
Table 4 verification of extraction Process
Tab 4 Results of process validation
Figure BDA0002306747340000121
The determination of the extract yield is innovatively implemented by determining the moisture content of the extracting solution by adopting a halogen moisture determination method, the extract yield is indirectly obtained, only about 6min is consumed, compared with the traditional oven drying to constant weight method, the time and energy are greatly saved, the test efficiency is improved, and the test accuracy is higher.
The test investigates the influence of acetonitrile-0.1% phosphoric acid aqueous solution, acetonitrile-0.2% phosphoric acid water-potassium dihydrogen phosphate and other mobile phase systems on the separation of berberine hydrochloride components, and finds that the berberine hydrochloride chromatographic peak can be better separated from other chromatographic peaks by adopting the acetonitrile-0.2% phosphoric acid aqueous solution mobile phase system through gradient elution without adopting buffer salts (potassium dihydrogen phosphate, sodium dodecyl sulfate and the like), and the theoretical plate number is not lower than 50000 calculated by the berberine hydrochloride.
Because berberine hydrochloride is the main effective component of the monarch drug phellodendron in the prescription, the content of the berberine hydrochloride has larger influence on the clinical curative effect after compatibility, therefore, the content of the berberine hydrochloride is selected as one of the evaluation indexes, the weight coefficient is higher, and is preferably 0.7; the extract yield is used as a reference index of the extraction process, can partially reflect the extraction quality of the prescription medicine, but the extract yield and the curative effect are not in a direct proportional relation, so the weight coefficient is relatively small in comprehensive evaluation, and is preferably 0.3.
And (4) conclusion:
the range analysis results of the orthogonal test show that the extraction times have significant influence on the test. Therefore, the experiment was added to the number of extractions, and the results showed the optimum extraction process (A)2B2C3) No obvious difference exists, and from the comprehensive benefits of production, the factors of energy conservation, consumption reduction, production period shortening and the like are considered, and the optimal level combination of all the factors is finally determined to be A2B2C3. Namely, the water addition times is 10 times, the decoction time is 1 hour, and the extraction times are 3 times.
Examples
The application method of the enema for eliminating mass and removing stasis provided by the invention comprises the following steps:
when in use, the medicine is convenient to absorb, and a patient firstly urinates and defecates to relieve abdominal pressure and clean the intestinal tract. The patient lies on the side, the trousers are taken off to the knee, the buttocks are moved close to the bed edge, the buttocks are raised by about 10cm, the rubber pad and the treatment towel are arranged below the buttocks, the liquid medicine is filled into the enema bag, the preheating temperature is 39-40 ℃, the enema bag is hung on a transfusion stand, the liquid level in the bag is about 40-60 cm higher than the anus, the liquid medicine is connected with the anal tube, the front section of the anal tube is lubricated, a small amount of liquid medicine is discharged, and the gas in the anal tube is discharged. Clamping anal canal, separating buttocks, exposing anus, inserting anal canal by about 15cm, and releasing the clamp. The speed of filling the liquid medicine is preferably slow, the filling amount is about 100ml, after the catheter is pulled out, the anus is gently massaged by using toilet paper to facilitate the liquid medicine to be remained, and the liquid medicine is remained for more than 1 hour as far as possible.
Specific clinical cases
Case 1, namely, plum, 24 years old, er yuan county, ri, ca, chronic pelvic inflammatory disease, 1 year and half, with symptoms: the lower abdomen is swollen and painful, the waist is sour, the belt is mostly smelly, the symptom disappears after 3 months of enema of the mass-eliminating and stasis-removing enema liquid which is detected in a left accessory area and 4.3 multiplied by 3.2 multiplied by 2.5cm low echo enclosed mass by B ultrasonic examination.
Case 2, 36 years old, chief subordinated, chronic pelvic inflammatory disease 2 and half years old, with symptoms: pain on one side of the lower abdomen with hard mass, pain when pressed, white or yellow leucorrhea, dry stool, dark red lips and tongue, and the symptoms disappear after 3 months of enema of the mass-eliminating and blood stasis-removing enema.
Case 3, Zhao Zhi, 47 years old, Dali Zhou He Qing county, chronic pelvic inflammatory disease for 4 years, with symptoms: the lower abdomen psychroalgia, clear and thin leucorrhea, pale complexion, mental fatigue, tiredness, aversion to cold, cold hands and feet, short breath, dislike of speaking, light headedness, loose stool, clear and long urine and pale tongue, and the symptoms disappear after 3 months of administration of the mass-eliminating and blood stasis-removing enema.
Social benefits are as follows: at present, the development and construction of the traditional Chinese medicine hospital face an important historical development opportunity and also face a challenge, the establishment of important special departments is a core development task of the traditional Chinese medicine hospital, and the special departments have special diseases and special medicines. Through the development of obstetrics and gynecology in our hospital for many years, a good public praise has been established in the market, and the hospital has own dominant disease species and standard clinical diagnosis and treatment schemes, such as diagnosis and treatment of pelvic inflammation and the like. The gynecological enema liquid has been clinically applied for many years, is decocted by nurses or decoction rooms all the time, cannot control the quality of the gynecological enema liquid, and is inconvenient for patients to use. The Chinese medicinal preparation is developed in hospital, can ensure the curative effect and safety of medication, is convenient for patients to use and nurses to operate, enlarges the influence of obstetrics and gynecology department and hospitals, perfects the diagnosis and treatment of dominant disease species, promotes the construction of key special departments, and the like.
Economic benefits are as follows: the dosage of the gynecological enema liquid is 1 time (bottle)/day, 10 days/course, and generally 3 courses, namely 30 bottles/person. The number of patients with pelvic inflammation in outpatients and inpatients in obstetrics and gynecology department is about 100 persons/month, and 3000 bottles/month are total. Net profit contract: 10 yuan/bottle, total net profit contract: 30000 yuan/month.
In the description herein, references to the description of "one embodiment," "an example," "a specific example" or the like are intended to mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The preferred embodiments of the invention disclosed above are intended to be illustrative only. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. Obviously, many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and the practical application, to thereby enable others skilled in the art to best utilize the invention. The invention is limited only by the claims and their full scope and equivalents.

Claims (4)

1. A mass-eliminating stasis-removing enema is characterized in that: the traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 170g of patrinia 130-containing material, 170g of crude phellodendron bark 130-containing material, 170g of sargentgloryvine stem 130-containing material, 170g of astragalus root 130-containing material, 70-130g of angelica, 50-70g of salvia miltiorrhiza, 50-70g of ligusticum wallichii, 50-70g of fried rhizoma corydalis, 170g of coix seed 130-containing material, 170g of garden balsam stem 130-containing material, 50-70g of cordate houttuynia, 50-70g of zedoary and 50-70g of crude licorice.
2. The stasis-eliminating enema liquid of claim 1, wherein: the mass-eliminating stasis-removing enema comprises the following traditional Chinese medicine raw materials in parts by weight: 150g of herba patriniae, 150g of raw phellodendron, 150g of sargentgloryvine stem, 150g of astragalus, 100g of angelica, 60g of salvia miltiorrhiza, 60g of ligusticum wallichii, 60g of fried rhizoma corydalis, 150g of coix seed, 150g of garden balsam stem, 60g of houttuynia cordata, 60g of roasted rhizoma zedoariae and 60g of raw liquorice.
3. The method for preparing a stasis-eliminating enema according to claim 1 or 2, wherein the mass-eliminating enema comprises:
the preparation method comprises the following steps:
respectively weighing 20 parts of herba patriniae, 20 parts of raw phellodendron, 20 parts of sargentgloryvine stem, 20 parts of astragalus, 13.3 parts of angelica, 8 parts of salvia miltiorrhiza, 8 parts of ligusticum wallichii, 8 parts of fried rhizoma corydalis, 20 parts of semen coicis, 20 parts of garden balsam stem, 8 parts of houttuynia cordata, 8 parts of roasted rhizoma zedoariae and 8 parts of raw liquorice;
soaking in 10 times of water for 30min, decocting for 3 times respectively, adding 10 times of water each time for 1 hr, filtering the extractive solution, and mixing filtrates;
separating with tube centrifuge (15000r/min) to obtain clear solution, concentrating to relative density of 1.05-1.15, and packaging;
sterilizing in a rapid cooling sterilizer (sterilization parameter of 121 deg.C, 30min) to obtain enema for removing blood stasis.
4. The use of a stasis-eliminating enema liquid according to claim 1 or 2 in the treatment of pelvic inflammatory disease.
CN201911242872.8A 2019-12-06 2019-12-06 Enema for eliminating mass and removing blood stasis and preparation method thereof Pending CN110859940A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911242872.8A CN110859940A (en) 2019-12-06 2019-12-06 Enema for eliminating mass and removing blood stasis and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911242872.8A CN110859940A (en) 2019-12-06 2019-12-06 Enema for eliminating mass and removing blood stasis and preparation method thereof

Publications (1)

Publication Number Publication Date
CN110859940A true CN110859940A (en) 2020-03-06

Family

ID=69658487

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911242872.8A Pending CN110859940A (en) 2019-12-06 2019-12-06 Enema for eliminating mass and removing blood stasis and preparation method thereof

Country Status (1)

Country Link
CN (1) CN110859940A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101391065A (en) * 2008-11-03 2009-03-25 刘文华 Compound semen momordicae and pepper soup for treating acute and chronic pelvic inflammatory diseases
CN102631589A (en) * 2012-03-31 2012-08-15 付正英 Penyanxiao enema and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101391065A (en) * 2008-11-03 2009-03-25 刘文华 Compound semen momordicae and pepper soup for treating acute and chronic pelvic inflammatory diseases
CN102631589A (en) * 2012-03-31 2012-08-15 付正英 Penyanxiao enema and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王刘英: "《康妇炎胶囊配合中药保留灌肠治疗盆腔炎60例》", 《云南中医中药杂志》 *

Similar Documents

Publication Publication Date Title
CN100375634C (en) A pharmaceutical used for moxibustion and preparation method thereof
CN102772781B (en) Traditional Chinese medicine preparation for treating chronic colitis and preparation method thereof
CN104274788A (en) Traditional Chinese medicine composition for treating morbid leucorrhea due to liver-fire and damp-heat in women and preparation method of traditional Chinese medicine composition
CN102018807A (en) Medicine composition for treating gynaecologic trichomonas vaginitis and preparation method thereof
CN103041247B (en) Traditional Chinese medicine suppository for curing colpitis and preparation method thereof
CN104587302A (en) Traditional Chinese medicine preparation for treating acute appendicitis
CN101732614B (en) Chinese medicament for treating urinary tract infection
CN103272019B (en) Traditional Chinese medicinal composition for treating wind-heat and intestine-dryness type haememorrhoids
CN105497723A (en) Traditional Chinese medicine preparation for treating bacterial pneumonia and preparation method thereof
CN102335367B (en) Medicine for treating pelvic inflammation
CN104587402B (en) A kind of Chinese medicine preparation for the treatment of chronic pelvic inflammatory disease and preparation method thereof
CN103301353A (en) Pharmaceutical composition for treating atrophic vaginitis
CN103285284A (en) Medical composition for treating senile vaginitis
CN110859940A (en) Enema for eliminating mass and removing blood stasis and preparation method thereof
CN105194165B (en) Traditional Chinese medicine used for treating infection of urinary system and preparation method thereof
CN104352910A (en) Traditional Chinese medicine external suppository for treating women morbid leucorrhea and preparation method thereof
CN105056201A (en) Chinese herba preparation for curing plasma cell mastitis and preparation method thereof
CN104383135A (en) Traditional Chinese medicine preparation for treating erysipelas and application method of traditional Chinese medicine preparation
CN103520638B (en) A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof
CN103623287B (en) A kind ofly treat Chinese medicine lotion of vaginitis and cervical erosion and preparation method thereof
CN103301373A (en) Pharmaceutical composition for treating postpartum perineal mucosal lesions
CN103054991A (en) Traditional Chinese medicine composition for treating lower abdominal discomfort, as well as preparation method and use thereof
CN102988847A (en) Medicine composition used for treating vaginitis
CN105396007A (en) Gynecological topical lotion for preventing and treating colpitis mycotica
CN106166209A (en) For promoting I phase, II phase pressure ulcer healing, the antiinfectious powder of Bedsore prevention III phase

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200306